16P - Prognostic value of cyclooxygenase 2, enhancer of zeste homolog 2 and p53 evaluated by quantitative image analysis in malignant NSCLC

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Kyriakos Hainis
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors K. Hainis1, A.M. Athanasiadou2, E. Haini3, A. Tsipis2, M. Gonidi4, P. Athanassiadou2
  • 1Pulmonary, Corfu General Hospital, 49100 - Corfu/GR
  • 2Pathology Laboratory, Medical School, University of Athens, Athens/GR
  • 3Pulmonary, Corfu General Hospital, Corfu/GR
  • 4Cytology Lab, Corfu General Hospital, Corfu/GR


Cyclooxygenase 2 (COX-2), Enhancer of Zeste Homolog 2 (EZH-2) and p53 overexpression is seen in many malignancies including lung cancer. The aim of this study was to investigate the usefulness of the expression of COX-2, p53 and EZH-2 in NSCLC using an image analysis system on immunostained specimens with regard to biological behavior of the tumor.